目的 探討利奈唑胺聯(lián)合鹽酸氨溴索治療新生兒重癥肺炎的臨床效果。方法 選擇咸陽市第一人民醫(yī)院2017年5月-2019年5月收治的重癥肺炎新生兒患者62例，按照隨機數(shù)字表法分為對照組和觀察組，每組各31例。對照組在常規(guī)治療的基礎上靜脈輸注鹽酸氨溴索注射液，7.5 mg/次，2次/d。觀察組在對照組治療的基礎上聯(lián)合使用利奈唑胺注射液，按照每8 h 10 mg/kg劑量iv。兩組連續(xù)治療10~14 d。觀察兩組患者的臨床療效，比較兩組的臨床指標和炎癥因子水平。結(jié)果 治療后，觀察組臨床總有效率為96.77%，明顯優(yōu)于對照組77.42%（P<0.05）。治療后，觀察組肺部啰音完全消失時間、肺功能和血氣分析指標恢復時間、住院時間等指標均明顯短于對照組（P<0.05）。治療后，兩組白細胞介素-2（IL-2）、白細胞介素-6（IL-6）、腫瘤細胞壞死因子-α（TNF-α）、C反應蛋白（CRP）水平均明顯降低，轉(zhuǎn)化生長因子β（TGF-β）水平明顯升高（P<0.05），且觀察組炎癥因子水平改善程度明顯優(yōu)于對照組（P<0.05）。結(jié)論 利奈唑胺聯(lián)合鹽酸氨溴索治療新生兒重癥肺炎后能夠明顯提高臨床療效，調(diào)節(jié)血清炎癥因子水平，促進抗炎和促炎因子間動態(tài)平衡的恢復，改善臨床癥狀，縮短住院時間，效果顯著，可推廣使用。

Objective To investigate the clinical effect of ambroxol hydrochloride combined with linezolid in treatment of severe pneumonia in neonates. Methods A total of 62 neonates with severe pneumonia in the First People's Hospital of Xianyang from May 2017 to May 2019 were selected as the study subjects. According to the random number table method, neonates were divided into control and observation groups, and each group had 31 cases. Neonates in the control group were iv administered with Ambroxol Hydrochloride Injection on the basis of conventional treatment at 7.5 mg/time, twice daily. Neonates in the observation group were iv administered with Linezolid Injection on the basis of control group, injected intravenously at a dose of 10 mg/kg every 8 h. Two groups were treated continuously for 10-14 d. After treatment, the clinical efficacy in two groups were observed, and the clinical indicators and levels of inflammatory factors in two groups were compared. Results After treatment, the total effective rate in the observation group was 96.77%, which was significantly better than 77.42% of the control group (P<0.05). After treatment, the lung rales disappeared, the recovery time of lung function and blood gas indicators, and the length of hospital stay in the observation group were significantly shorter than those in the control group (P<0.05). After treatment, the levels of IL-2, IL-6, TNF-α, and CRP in two groups were significantly decreased, but TGF-β levels were significantly increased (P<0.05), and the inflammatory factors levels in the observation group were significantly better than those in the control group (P<0.05). Conclusion ambroxol hydrochloride combined with linezolid in treatment of severe pneumonia in newborns can significantly improve the clinical efficacy, regulate the level of serum inflammatory factors, promote the recovery of the dynamic balance between antiinflammatory and pro-inflammatory factors, improve clinical symptoms, and shorten the length of hospital stay, the effect is significant, it can be widely used.

R974.2;R985